The largest ever retrospective study of cervical cancer screening strategies, conducted by Quest Diagnostics Health Trends™, found that 1 out of 5 cases of cervical cancer was missed with HPV-Alone* screening. Based on the 12,360 women who are estimated to be diagnosed with cervical cancer every year, this means that 2,400 women could be missed annually with HPV-Alone* screening.1
The study contained 65 times more cancer cases than the clinical trial that led to the FDA approval of the additional indication for HPV-Alone* screening for an existing HPV test.
Data from approximately 8.6 million women ages 30 to 65 were analyzed, with over a quarter of a million of these women having received a cervical cancer biopsy based on their screening results.1,2
Read the full Quest Study publication here.
The facts are clear: Screening with Pap+HPV Together provides the best possible protection against cervical cancer for women ages 30 to 65, and guidelines as well as data support this.1, 3‑5
We can't afford to introduce more risk into women's lives with HPV-Alone* screening.
We’ve made a lot of progress in the fight against cervical cancer - we can’t afford to let risk back into women’s lives with HPV-Alone screening.
- Dr. Marshall Austin